Previous 10 | Next 10 |
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET to discuss third quarte...
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035 shares of its common stock, which includes 210,526 shares sold upon the full exercise of ...
Gainers: Universal Security Instruments (UUU) +69%.Polar Power (POLA) +37%.Rekor Systems (REKR) +35%.Entercom Communications (ETM) +33%.Pinterest (PINS) +29%.Inphi (IPHI) +28%.Forte Biosciences (FBRX) +21%.Meta Financial Group (CASH) +19%.Novus Therapeutics (NVUS) +18%.Dig...
Gainers: vTv Therapeutics (VTVT) +22%, Forte Biosciences (FBRX) +20%, Penumbra (PEN) +14%, Cellect Biotechnology (APOP) +10%, Inari Medical (NARI) +10%.Losers: Tricida (TCDA) -52%, Cancer Genetics (CGIX) -34%., Constellation Pharmaceutica...
Forte Biosciences ([[FBRX]] +18.3%) has priced public offering of ~1.4M common shares at $28.50/share, for gross proceeds od ~$40M.Underwriters' over-allotment is an additional 210,526 shares. Net proceeds will be used for working capital and general corporate purposes.Closing date is Novembe...
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted to the underwriters a 3...
Forte Biosciences (FBRX) has commenced an underwritten public offering of its common stock.Volume, price are yet to be determined. For further details see: Forte Biosciences readies equity offering
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up t...
The FDA has designated Forte Biosciences's (FBRX) FB-401 for fast track review for the treatment of atopic dermatitis (also known eczema).FB-401 is a topically applied live biotherapeutic consisting of specifically selected strains of commensal Roseomonas mucosa.Atopic dermatitis is an...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis. FB-401 is a topically ...
News, Short Squeeze, Breakout and More Instantly...
Forte Biosciences Inc. Company Name:
FBRX Stock Symbol:
NASDAQ Market:
Forte Biosciences Inc. Website:
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. First Quarter 2024 Business Highlights ȁ...
Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. 2023 Business Highlights “Forte achieved a major...